Nanoparticles and targeted drug delivery in cancer therapy
•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach. Surgery, chemotherapy, radiotherapy, and hormone therapy are the main...
Gespeichert in:
Veröffentlicht in: | Immunology letters 2017-10, Vol.190, p.64-83 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 83 |
---|---|
container_issue | |
container_start_page | 64 |
container_title | Immunology letters |
container_volume | 190 |
creator | Bahrami, Behdokht Hojjat-Farsangi, Mohammad Mohammadi, Hamed Anvari, Enayat Ghalamfarsa, Ghasem Yousefi, Mehdi Jadidi-Niaragh, Farhad |
description | •Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach.
Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs. |
doi_str_mv | 10.1016/j.imlet.2017.07.015 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_495055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165247817301761</els_id><sourcerecordid>1925271859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</originalsourceid><addsrcrecordid>eNp9kU1P3DAQhi1EVbbQX4BU5cglW38mdiUOCNEPCZULnC3HMwEv2SS1E9D-e7zdhZ6KNJJH1vPOO5qXkFNGl4yy6utqGdYdTktOWb2kuZg6IAuma1NSJfkhWWRKlVzW-oh8SmlFMyGk-EiOuK4rKo1ZkG-_XT-MLk7Bd5gK10MxuXiPE0IBcb4vALvwhHFThL7wrvcYi-kBoxs3J-RD67qEn_fvMbn7fnV7-bO8vvnx6_LiuvRS1lOpleYAogEpBFNtzcAbX1XgQDEAw7WpKoPOe95q13BVUWM0NDVtuVPCO3FMyt3c9Izj3NgxhrWLGzu4YPdfj7lDK42iSmXe_Jcf4wD_RK9CJirNNVcya8922gz-mTFNdh2Sx65zPQ5zssxwxWumlcmo2KE-DilFbN-MGLXbgOzK_g3IbgOyNBfbLvdlbzA3a4Q3zWsiGTjfAZhP-hQw2uQD5rtDiOgnC0N41-AF9mqkBw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1925271859</pqid></control><display><type>article</type><title>Nanoparticles and targeted drug delivery in cancer therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bahrami, Behdokht ; Hojjat-Farsangi, Mohammad ; Mohammadi, Hamed ; Anvari, Enayat ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Jadidi-Niaragh, Farhad</creator><creatorcontrib>Bahrami, Behdokht ; Hojjat-Farsangi, Mohammad ; Mohammadi, Hamed ; Anvari, Enayat ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Jadidi-Niaragh, Farhad</creatorcontrib><description>•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach.
Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.</description><identifier>ISSN: 0165-2478</identifier><identifier>ISSN: 1879-0542</identifier><identifier>EISSN: 1879-0542</identifier><identifier>DOI: 10.1016/j.imlet.2017.07.015</identifier><identifier>PMID: 28760499</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; Cancer immunotherapy ; Drug Delivery Systems ; Drug-Related Side Effects and Adverse Reactions - prevention & control ; Humans ; Medicin och hälsovetenskap ; Nanoparticles ; Nanoparticles - therapeutic use ; Neoplasms - drug therapy ; Targeted drug delivery</subject><ispartof>Immunology letters, 2017-10, Vol.190, p.64-83</ispartof><rights>2017 European Federation of Immunological Societies</rights><rights>Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</citedby><cites>FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.imlet.2017.07.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28760499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:136828254$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Bahrami, Behdokht</creatorcontrib><creatorcontrib>Hojjat-Farsangi, Mohammad</creatorcontrib><creatorcontrib>Mohammadi, Hamed</creatorcontrib><creatorcontrib>Anvari, Enayat</creatorcontrib><creatorcontrib>Ghalamfarsa, Ghasem</creatorcontrib><creatorcontrib>Yousefi, Mehdi</creatorcontrib><creatorcontrib>Jadidi-Niaragh, Farhad</creatorcontrib><title>Nanoparticles and targeted drug delivery in cancer therapy</title><title>Immunology letters</title><addtitle>Immunol Lett</addtitle><description>•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach.
Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer immunotherapy</subject><subject>Drug Delivery Systems</subject><subject>Drug-Related Side Effects and Adverse Reactions - prevention & control</subject><subject>Humans</subject><subject>Medicin och hälsovetenskap</subject><subject>Nanoparticles</subject><subject>Nanoparticles - therapeutic use</subject><subject>Neoplasms - drug therapy</subject><subject>Targeted drug delivery</subject><issn>0165-2478</issn><issn>1879-0542</issn><issn>1879-0542</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1P3DAQhi1EVbbQX4BU5cglW38mdiUOCNEPCZULnC3HMwEv2SS1E9D-e7zdhZ6KNJJH1vPOO5qXkFNGl4yy6utqGdYdTktOWb2kuZg6IAuma1NSJfkhWWRKlVzW-oh8SmlFMyGk-EiOuK4rKo1ZkG-_XT-MLk7Bd5gK10MxuXiPE0IBcb4vALvwhHFThL7wrvcYi-kBoxs3J-RD67qEn_fvMbn7fnV7-bO8vvnx6_LiuvRS1lOpleYAogEpBFNtzcAbX1XgQDEAw7WpKoPOe95q13BVUWM0NDVtuVPCO3FMyt3c9Izj3NgxhrWLGzu4YPdfj7lDK42iSmXe_Jcf4wD_RK9CJirNNVcya8922gz-mTFNdh2Sx65zPQ5zssxwxWumlcmo2KE-DilFbN-MGLXbgOzK_g3IbgOyNBfbLvdlbzA3a4Q3zWsiGTjfAZhP-hQw2uQD5rtDiOgnC0N41-AF9mqkBw</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Bahrami, Behdokht</creator><creator>Hojjat-Farsangi, Mohammad</creator><creator>Mohammadi, Hamed</creator><creator>Anvari, Enayat</creator><creator>Ghalamfarsa, Ghasem</creator><creator>Yousefi, Mehdi</creator><creator>Jadidi-Niaragh, Farhad</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20171001</creationdate><title>Nanoparticles and targeted drug delivery in cancer therapy</title><author>Bahrami, Behdokht ; Hojjat-Farsangi, Mohammad ; Mohammadi, Hamed ; Anvari, Enayat ; Ghalamfarsa, Ghasem ; Yousefi, Mehdi ; Jadidi-Niaragh, Farhad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-8582dd3bd43315f71dc9c66dad51dd9289669eacc2f8ab2560998db70f2a53ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer immunotherapy</topic><topic>Drug Delivery Systems</topic><topic>Drug-Related Side Effects and Adverse Reactions - prevention & control</topic><topic>Humans</topic><topic>Medicin och hälsovetenskap</topic><topic>Nanoparticles</topic><topic>Nanoparticles - therapeutic use</topic><topic>Neoplasms - drug therapy</topic><topic>Targeted drug delivery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bahrami, Behdokht</creatorcontrib><creatorcontrib>Hojjat-Farsangi, Mohammad</creatorcontrib><creatorcontrib>Mohammadi, Hamed</creatorcontrib><creatorcontrib>Anvari, Enayat</creatorcontrib><creatorcontrib>Ghalamfarsa, Ghasem</creatorcontrib><creatorcontrib>Yousefi, Mehdi</creatorcontrib><creatorcontrib>Jadidi-Niaragh, Farhad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Immunology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bahrami, Behdokht</au><au>Hojjat-Farsangi, Mohammad</au><au>Mohammadi, Hamed</au><au>Anvari, Enayat</au><au>Ghalamfarsa, Ghasem</au><au>Yousefi, Mehdi</au><au>Jadidi-Niaragh, Farhad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanoparticles and targeted drug delivery in cancer therapy</atitle><jtitle>Immunology letters</jtitle><addtitle>Immunol Lett</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>190</volume><spage>64</spage><epage>83</epage><pages>64-83</pages><issn>0165-2478</issn><issn>1879-0542</issn><eissn>1879-0542</eissn><abstract>•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug delivery by nanomaterials is an effective anti-cancer therapeutic approach.
Surgery, chemotherapy, radiotherapy, and hormone therapy are the main common anti-tumor therapeutic approaches. However, the non-specific targeting of cancer cells has made these approaches non-effective in the significant number of patients. Non-specific targeting of malignant cells also makes indispensable the application of the higher doses of drugs to reach the tumor region. Therefore, there are two main barriers in the way to reach the tumor area with maximum efficacy. The first, inhibition of drug delivery to healthy non-cancer cells and the second, the direct conduction of drugs into tumor site. Nanoparticles (NPs) are the new identified tools by which we can deliver drugs into tumor cells with minimum drug leakage into normal cells. Conjugation of NPs with ligands of cancer specific tumor biomarkers is a potent therapeutic approach to treat cancer diseases with the high efficacy. It has been shown that conjugation of nanocarriers with molecules such as antibodies and their variable fragments, peptides, nucleic aptamers, vitamins, and carbohydrates can lead to effective targeted drug delivery to cancer cells and thereby cancer attenuation. In this review, we will discuss on the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by NPs.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28760499</pmid><doi>10.1016/j.imlet.2017.07.015</doi><tpages>20</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-2478 |
ispartof | Immunology letters, 2017-10, Vol.190, p.64-83 |
issn | 0165-2478 1879-0542 1879-0542 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_495055 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Antineoplastic Agents - therapeutic use Cancer immunotherapy Drug Delivery Systems Drug-Related Side Effects and Adverse Reactions - prevention & control Humans Medicin och hälsovetenskap Nanoparticles Nanoparticles - therapeutic use Neoplasms - drug therapy Targeted drug delivery |
title | Nanoparticles and targeted drug delivery in cancer therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A42%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanoparticles%20and%20targeted%20drug%20delivery%20in%20cancer%20therapy&rft.jtitle=Immunology%20letters&rft.au=Bahrami,%20Behdokht&rft.date=2017-10-01&rft.volume=190&rft.spage=64&rft.epage=83&rft.pages=64-83&rft.issn=0165-2478&rft.eissn=1879-0542&rft_id=info:doi/10.1016/j.imlet.2017.07.015&rft_dat=%3Cproquest_swepu%3E1925271859%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1925271859&rft_id=info:pmid/28760499&rft_els_id=S0165247817301761&rfr_iscdi=true |